Primeiro relato de Hysterothylacium deardorffoverstreetorum (Raphidascarididae) em bijupirá de criação, Rachycentron canadum (Linnaeus 1766), no Brasil / First report of Hysterothylacium deardorffoverstreetorum (Raphidascarididae) in cobia (Rachycentron canadum (Linnaeus 1766) farming in Brazil

O objetivo do presente estudo foi registrar a ocorrência de larva de nematoide da família Raphidascarididae, Hysterothylacium deardorffoverstreetorum, em bijupirá Rachycentron canadum (Linnaeus, 1766), criado e alimentado com ração e "trashfish" em fazendas marinhas localizadas no Rio de Janeiro, Brasil, alertando para possíveis riscos zoonóticos ao se usar esse tipo de alimentação para criação de peixes. Foram necropsiados 15 animais. Os parasitas encontrados foram coletados, fixados e, posteriormente, conservados em álcool a 70°GL, clarificados e identificados. Em todos os animais necropsiados, apenas um espécime estava parasitado com uma larva de Hysterothylacium deardorffoverstreetorum na serosa do fígado do peixe e conclui-se que a presença desse parasita em bijupirá de criação alimentado por "trashfish pode estar associada à alimentação, indicando, assim, um potencial risco zoonótico.(AU)

The aim of this study was to record the occurrence of nematode larvae of the Raphidascarididae family, Hysterothylacium deardorffoverstreetorum in cobia Rachycentron canadum (Linnaeus, 1766) grown and fed with trashfish in marine farms located in Rio de Janeiro, Brazil, warning regarding possible zoonotic risk using this type of food for fish. Fifteen animals were necropsied. Parasites found were collected, fixed and later preserved in alcohol 70°GL, clarified and identified. In all animals necropsied, only one specimen was infested with a Hysterothylacium deardorffoverstreetorum larvae in the serosa of fish liver. It is concluded that the presence of the parasite in cobia culture fed with trashfish may be associated with a potential zoonotic risk.(AU)

Quetiapine versus clomipramine in the augmentation of selective serotonin reuptake inhibitors for the treatment of obsessive-compulsive disorder: a randomized, open-label trial.

After 12 weeks of selective serotonin reuptake inhibitor (SSRI) monotherapy with inadequate response, 10 patients received clomipramine and 11 received quetiapine as augmentation agents of the SSRI. The primary outcome measure was the difference between initial and final scores of the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS), rated in a blinded fashion, and the score of clinical global improvement (CGI-I). Statistical analyses were performed using nonparametric tests to evaluate treatment efficacy and the difference between treatment groups. Percentile plots were constructed with YBOCS scores from the clomipramine and quetiapine groups. Considering response a >or=35% reduction in the initial Y-BOCS score plus a rating of 'much improved' or 'very much improved' on CGI-I, four of eleven quetiapine patients and one out of ten clomipramine patients were classified as responders. The mean final Y-BOCS score was significantly lower than baseline in the quetiapine augmentation group (P = 0.023), but not in the clomipramine augmentation group (P = 0.503). The difference between groups showed a trend towards significance only at week 4, the mean Y-BOCS score being lower for those receiving quetiapine (P = 0.052). A difference between groups was also observed at week 4 according to percentile plots. These results corroborate previous findings of quetiapine augmentation efficacy in obsessive-compulsive disorder (OCD). Clomipramine augmentation did not produce a significant reduction in Y-BOCS scores. Higher target maximum dosages might have yielded different results.